Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.
Expert Rev Endocrinol Metab. 2008;3(5):577-592. Disclosure: The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or ...